Investigational drug · Phase 2
VS-101
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Head and Neck Cancer Squamous Cell Carcinoma.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 2, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "VS-101"
First trial start
2025
Jun 11, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "VS-101", any sponsor or status.
Conditions studied
As listed on its trial records.
- Head and Neck Cancer Squamous Cell Carcinoma
Approved drugs for the same conditions: Head and neck cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "VS-101" as an intervention, largest first.
ViSci Ltd.Industry
NCT02129673 · 77 participants · Start May 2014 · Primary completion May 2017
Drug: VS101 Insert Dose A; VS101 Insert Dose B and 2 more · For: Open Angle Glaucoma; Ocular Hypertension
Sites: Bellevue, Washington
VSPharmTech Co.,Ltd.Industry
NCT06959082 · 30 participants (planned) · Start Jun 11, 2025 · Primary completion Dec 2027
Drug: VS-101; Cisplatin · For: Head and Neck Cancer Squamous Cell Carcinoma
Sites: New Haven, Connecticut; Manhattan, New York
Newest research
PubMed records naming it or its code names, newest first.
- Real-World Outcomes After Dupilumab Initiation for Pediatric Chronic Rhinosinusitis with Nasal Polyps.
Haji MS, Kassem AA, Ibrahim AF, et al. · Otolaryngol Head Neck Surg 2026
- Manual ventilation with and without a flow limiting device during induction of general anesthesia: a randomized crossover trial.
Brady MF, Ramanujam V, Dankievitch K, et al. · Resusc Plus 2026
- Assessment of essential and toxic trace element imbalances in hypothyroid patients with and without levothyroxine therapy: a case-control study.
Ammar A, Al-Fartusie FS · Biometals 2026
- Spectrum and immunovirological determinants of tumours among people living with HIV in Uganda: A retrospective cross sectional study from a specialised HIV centre, 2017-2026.
Mwaka J, Sserunjogi C, Natalayi J · PLoS One 2026
- Outcomes of Transfer Destination in Patients With STEMI: Enhanced Community Hospital vs Quaternary Medical Center.
Gilchrist IC, Read AEP, Makaryus AN, et al. · JACC Case Rep 2026
- Prolonged Continuous Theta Burst Stimulation With Transcranial Magnetic Stimulation Analgesic Effects and Corticospinal Excitability in Chronic Neuropathic Pain: A Randomized Clinical Trial.
Liu Y, Che X, Sun J, et al. · Anesth Analg 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.